A study to compare the relative bioavailability of Fatak Chemie Pars and Eisai formulations of zonisamide 100 mg tablets in 24 healthy adult volunteers under fasting conditions
The study aims to evaluate the bioequivalence of zonisamide 100 mg tablets produced by two different pharmaceutical companies under fasting conditions
Design
This randomized, single-dose, two-way, crossover study is conducted to compare the pharmacokinetics of zonisamide and Zonegran® tablets in 24 healthy adult volunteers. Volunteers will be sorted and receive a number from 1 to 24. In the first phase of the study, 12 volunteers will receive zonisamide manufactured by Fatak Chemie Pars and the remaining 12 volunteers will receive Zonegran® produced by Eisai company. The administered drugs will be replaced to another group in the second phase of the study.
Settings and conduct
The dose administration and subsequent sample collection will be performed in Motahhari hospital (Gonbade Kavous, Iran).
Participants/Inclusion and exclusion criteria
Inclusion criteria: aged 18-55 years; subject available for the entire study period; willingness to adhere to protocol requirements as evidenced by written informed consent; good health at screening. Exclusion criteria: History of use of any drug; hypersensitivity or intolerance; significant history or current evidence of chronic disease; receipt of any drug as part of a research study within 30 days prior to the present study.
Intervention groups
First intervention group: A single 200 mg oral dose of zonisamide (2 tablets) manufactured by Fatak Chemie Pars company to 12 subjects. Second intervention group: A single 200 mg oral dose of Zonegran (2 tablets) manufactured by Eisai company to 12 subjects. Since in this study, the volunteers will receive both test and reference drugs, each volunteer will act as his own control.
Main outcome variables
Drug plasma concentration; Area under the plasma concentration-time curve
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20130626013776N58
Registration date:2021-08-31, 1400/06/09
Registration timing:prospective
Last update:2021-08-31, 1400/06/09
Update count:0
Registration date
2021-08-31, 1400/06/09
Registrant information
Name
Hossein Amini
Name of organization / entity
Golestan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 17 1442 1651
Email address
hamini@sbmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-10-23, 1400/08/01
Expected recruitment end date
2022-10-23, 1401/08/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
A study to compare the relative bioavailability of Fatak Chemie Pars and Eisai formulations of zonisamide 100 mg tablets in 24 healthy adult volunteers under fasting conditions
Public title
Bioequivalence study of zonisamide 100 mg tablets
Purpose
Basic scienece
Inclusion/Exclusion criteria
Inclusion criteria:
18-55 years of age.
The subject is able and willing to provide signed informed consent.
The subject is available for the entire study period.
Willing to adhere to protocol requirements as evidenced by written informed consent.
The subject has a stable residence and telephone.
Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
Exclusion criteria:
History of allergy or sensitivity to zonisamide.
History of any drug hypersensitivity or intolerance which, in the opinion of the investigator,would compromise the safety of the subject of the study.
Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction.
Presence of gastrointestinal disease or history of malabsorption within the last year.
History of a medical disorders occurring within the last year that required hospitalization or medication.
Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
Receipt of any drug as part of a research study within 30 days prior to the present study.
Donation or significant loss of whole blood (480 ml or more) within 30 days prior to the present study.
Age
From 18 years old to 55 years old
Gender
Both
Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size:
24
More than 1 sample in each individual
Number of samples in each individual:
2
In a crossover design, each person is its own control and receives two different interventions
Randomization (investigator's opinion)
Randomized
Randomization description
A pot randomization method will be used in this study. 12 papers are labeled "Reference Product" and 12 papers are written as "Test Product". The papers are then placed in sealed envelopes, and participants randomly select a paper and will be placed in the Reference or Test groups.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics Committee of Golestan University of Medical Sciences
Street address
Falsafi Building, Sari Road Km 2
City
Gorgan
Province
Golestan
Postal code
4934174515
Approval date
2021-06-27, 1400/04/06
Ethics committee reference number
IR.GOUMS.REC.1400.121
Health conditions studied
1
Description of health condition studied
.
ICD-10 code
ICD-10 code description
Primary outcomes
1
Description
Drug plasma concentration
Timepoint
At time zero and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 24, 48, 96 and 144 h after drug administration
Method of measurement
Blood sampling and measurement of drug concentrations by high-performance liquid chromatography
2
Description
Area under plasma concentration-time curve
Timepoint
At time zero and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 24, 48, 96 and 144 h after drug administration
Method of measurement
Blood sampling and measurement of drug concentrations by high-performance liquid chromatography
Secondary outcomes
1
Description
Plasma half-life
Timepoint
From the terminal 140 hours of plasma concentration-time profile
Method of measurement
Blood sampling and drug analysis by high-performance liquid chromatography method
Intervention groups
1
Description
Intervention group: Oral administration of a single 200 mg dose of zonisamide (2 tablets) manufactured by Fatak Chemie Pars to healthy volunteers under fasting condition in the morning of the experiment day
Category
Treatment - Drugs
2
Description
Intervention group: Oral administration of a single 200 mg dose of Zonegran (2 tablets) manufactured by Eisai to healthy volunteers under fasting condition in the morning of the experiment day